CPT 81435: Hereditary Colon Cancer Gene Panel, Sequence + CNV
Commercial payers pay $797 on average nationally for this procedure.
CPT code 81435 describes a genomic sequence analysis panel for hereditary colon cancer–related disorders that evaluates a patient specimen for sequence variants and copy number variants across at least five genes; this molecular diagnostic service is typically performed by a laboratory or molecular pathology service and is billed for genetic testing of germline DNA, usually with specimen collection and analysis occurring in a clinical laboratory or hospital pathology setting.
Customize your policy alerts
Sign up for cpt 81435 policy alerts
Get alerted when payer policies referencing 81435 are released or updated.
Monitor payer policy activity
National Reimbursement Benchmarks
National commercial rates for CPT 81435 cluster around BUCA’s average commercial benchmark of $797.10, with substantial variation across individual carriers. Blue Cross Blue Shield shows the highest dispersion between its 25th and 75th percentiles (P75–P25 = $485.70), reflecting broader contractual variability, while Aetna and UnitedHealth Group display tighter mid‑range spreads (Aetna range = $227.70; UnitedHealth Group range = $240.20), indicating more consistency in negotiated commercial rates. Cigna’s interquartile spread ($877.80) is also wide, and BUCA’s own interquartile span ($391.00) sits between the narrowest and widest payers.
Mean rates further illustrate divergence: Blue Cross Blue Shield and Cigna have higher mean levels ($942.30 and $860.10, respectively) above BUCA’s average, while UnitedHealth Group and Aetna have lower means ($530.10 and $420.10). Payer-specific tails (P90) extend substantially for Blue Cross Blue Shield and Cigna, contributing to top-end variability in the commercial market for this code.